Skip to main content
Log in

Analgetikaintoleranz

Ein häufiges, interdisziplinäres Krankheitsbild

Aspirin-Intolerance-Syndrom

A common and interdisciplinary disease

  • Arzneimitteltherapie
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Überempfindlichkeitsreaktionen auf nichtsteroidale Antiphlogistika (NSAID), wie auf Acetylsalizylsäure, werden in Kombination mit Polyposis nasi und Asthma bronchiale als Morbus Widal (Samter Trias, Morbus Samter) bezeichnet, wobei der Begriff Aspirin-exacerbated Respiratory Disease (AERD) neuerdings favorisiert wird. Diese Pseudoallergie tritt bei bis zu 10% aller Asthmatiker auf und verursacht schwerwiegende, lebensbedrohliche oder anaphylaktische Episoden. Es handelt sich hierbei nicht um einen IgE-vermittelten Mechanismus, sondern um eine erworbene Dysbalance im Arachidonsäurestoffwechsel, welche durch die Aufnahme von nichtsteroidalen Antiphlogistika akut verstärkt wird. Die Patienten leiden auch ohne Einnahme von NSAID neben der genannten Symptomtrias an nasaler Obstruktion, wässriger Rhinorrhoe, Hyposmie, Urtikaria und/oder Angioödemen. Die Diagnose einer Analgetikaintoleranz lässt sich nur mit Hilfe eines Provokationstests stellen. Die Grundkrankheit wird mit topischen und systemischen Glukokortikosteroiden, β2-Sympathomimetika und Antileukotrienen behandelt, NSAID sind streng zu meiden. Eine spezifische Therapie steht mit der adaptiven Acetylsalizylsäuredesaktivierung zur Verfügung, von der gerade Patienten mit ansonsten behandlungsresistenten Verläufen profitieren.

Abstract

The full clinical picture of aspirin intolerance – the association of aspirin-induced bronchial asthma, aspirin sensitivity and nasal polyps – has been described as Morbus Widal or later as the “Samter triad”. Today the term Aspirin-exacerbated respiratory disease (AERD) is preferred to account for the progressive nature of this inflammatory airway condition with its unrelenting course even in the absence of non steroidal anti-inflammatory drugs (NSAID). This acquired idiosyncrasy appears to be related to an abnormal arachidonic acid metabolism. Epidemiological data suggests that 10% of all asthmatics do react with life-threatening asthma-attacks after the ingestion of aspirin (ASA) or other NSAID. Some asthmatics with nasal polyposis have been reported to suffer from aspirin intolerance. Although the exact mechanism is still unclear, it is unlikely that the pathogenesis is IgE-mediated. Patients often report chronic nasal obstruction, hyposmia, chronic rhinorrhoea, orbital edema and urticaria with flushing after the ingestion of NSAID. While a typical history and endoscopic findings can be suggestive of AERD, a definite diagnosis relies on appropriate challenge tests. AERD is often refractory to standard asthma treatment with systemic and inhaled steroids, β2-agonists, leukotrien-antagonists. Adaptive desactivation can induce a reversible tolerance to NSAID which also leads to an improvement in signs and symptoms of the underlying AERD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1

Literatur

  1. Arm JP, Austen KF (2002) Leukotriene receptors and aspirin sensitivity. N Engl J Med 347:1524–1526

    Article  PubMed  Google Scholar 

  2. Babu KS, Salvi SS (2000) Aspirin and asthma. Chest 118:1470–1476

    Article  PubMed  CAS  Google Scholar 

  3. Berges-Gimeno MP, Simon RA, Stevenson DD (2002) The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 89:474–478

    Article  PubMed  Google Scholar 

  4. Berges-Gimeno MP, Simon RA, Stevenson DD (2003) Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 111:180–186

    Article  PubMed  CAS  Google Scholar 

  5. Cowburn AS, Sladek K, Soja J et al (1998) Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 101:834–846

    Article  PubMed  CAS  Google Scholar 

  6. Dahlen SE (2006) Treatment of asthma with antileukotrienes: first line or last resort therapy? Eur J Pharmacol 533:40–56

    Article  PubMed  CAS  Google Scholar 

  7. Dollner R, Klimek L, Pfaar O et al (2007) In-vitro-Testverfahren bei Analgetika-Intoleranz. Allergologie 30:240–248

    Google Scholar 

  8. Gosepath J, Schaefer D, Amedee RG, Mann WJ (2001) Individual monitoring of aspirin desensitization. Arch Otolaryngol Head Neck Surg 127:316–321

    PubMed  CAS  Google Scholar 

  9. Klimek L, Pfaar O (2009) Aspirin intolerance: does desensitization alter the course of the disease? Immunol Allergy Clin North Am 29:669–675

    Article  PubMed  CAS  Google Scholar 

  10. Lee JY, Simon RA, Stevenson DD (2007) Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 119:157–164

    Article  PubMed  CAS  Google Scholar 

  11. Makowska JS, Grzegorczyk J, Bienkiewicz B et al (2008) Systemic responses after bronchial aspirin challenge in sensitive patients with asthma. J Allergy Clin Immunol 121:348–354

    Article  PubMed  CAS  Google Scholar 

  12. May A, Weber A, Gall H et al (1999) Means of increasing sensitivity of an in vitro diagnostic test for aspirin intolerance. Clin Exp Allergy 29:1402–1411

    Article  PubMed  CAS  Google Scholar 

  13. Molnar-Gabor E, Endreffy E, Rozsasi A (2000) HLA-DRB1, -DQA1, and -DQB1 genotypes in patients with nasal polyposis. Laryngoscope 110:422–425

    Article  PubMed  CAS  Google Scholar 

  14. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L et al (2007) EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 62:1111–1118

    Article  PubMed  CAS  Google Scholar 

  15. Parikh AA, Scadding GK (2005) Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial. Laryngoscope 115:1385–1390

    Article  PubMed  CAS  Google Scholar 

  16. Pfaar O, Klimek L (2006) Aspirin desensitization in aspirin intolerance: update on current standards and recent improvements. Curr Opin Allergy Clin Immunol 6:161–166

    PubMed  CAS  Google Scholar 

  17. Pfaar O, Klimek L (2006) Eicosanoids, aspirin-intolerance and the upper airways–current standards and recent improvements of the desensitization therapy. J Physiol Pharmacol 57 (Suppl 12):5–13

    PubMed  Google Scholar 

  18. Picado C (2002) Aspirin intolerance and nasal polyposis. Curr Allergy Asthma Rep 2:488–493

    Article  PubMed  Google Scholar 

  19. Rozsasi A, Polzehl D, Deutschle T et al (2008) Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 63:1228–1234

    Article  PubMed  CAS  Google Scholar 

  20. Samter M, Beers RF Jr (1968) Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 68:975–983

    PubMed  CAS  Google Scholar 

  21. Schafer D, Lindenthal U, Wagner M et al (1996) Effect of prostaglandin E2 on eicosanoid release by human bronchial biopsy specimens from normal and inflamed mucosa. Thorax 51:919–923

    Article  PubMed  CAS  Google Scholar 

  22. Stevenson DD (2009) Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Rep 9:155–163

    Article  PubMed  CAS  Google Scholar 

  23. Stevenson DD, Hankammer MA, Mathison DA et al (1996) Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 98:751–758

    Article  PubMed  CAS  Google Scholar 

  24. Szczeklik A, Nizankowska E, Bochenek G et al (2001) Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 31:219–225

    Article  PubMed  CAS  Google Scholar 

  25. Szczeklik A, Nizankowska E, Duplaga M (2000) Natural history of aspirin-induced asthma. AIANE Investigators. European network on aspirin-induced asthma. Eur Respir J 16:432–436

    Article  PubMed  CAS  Google Scholar 

  26. Szczeklik A, Sanak M, Nizankowska-Mogilnicka E, Kielbasa B (2004) Aspirin intolerance and the cyclooxygenase-leukotriene pathways. Curr Opin Pulm Med 10:51–56

    Article  PubMed  CAS  Google Scholar 

  27. Szczeklik A, Stevenson DD (1999) Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 104:5–13

    Article  PubMed  CAS  Google Scholar 

  28. Weck AL de, Sanz ML (2004) Cellular Allergen Stimulation Test (CAST) 2003, a review. J Investig Allergol Clin Immunol 14:253–273

    PubMed  Google Scholar 

  29. Widal F, Abrami P, Lermoyez J (1987) First complete description of the aspirin idiosyncrasy-asthma-nasal polyposis syndrome (plus urticaria) 1922 (with a note on aspirin desensitization). J Asthma 24:297–300

    Article  PubMed  CAS  Google Scholar 

  30. Zeiss C, Lockey RF (1976) Refractory period to aspirin in a patient with aspirin-induced asthma. J Allergy Clin Immunol 57:440–448

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to O. Pfaar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Umbreit, C., Virchow, J., Thorn, C. et al. Analgetikaintoleranz. Internist 51, 1196–1201 (2010). https://doi.org/10.1007/s00108-010-2661-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-010-2661-y

Schlüsselwörter

Keywords

Navigation